New Xarelto Lawsuit in Vermont Man dies of internal bleeding

By | December 2, 2015

The infamous blood thinner Xarelto probably killed another victim. The Novel Oral Anticoagulant (NOAC) drug produced by Bayer AG has been the target of several Xarelto lawsuits over the course of the last few years. Plaintiffs accuse the pharmaceutical company of fraudulent misrepresentation of the drug’s safety, negligence in providing adequate warning to patients as well as physicians about the risks and dangers, and personal injuries suffered because of the medication side effects. Xarelto has been marketed as a “safer” alternative to Warfarin and other anticoagulants, although the recent findings and events showed that this medication can cause severe harm to patients who use it. Although other NOACs such as Eliquis and Pradaxa are also associated with several cases of potentially lethal adverse reactions, Xarelto is often considered the most dangerous of them.

Xarelto uncontrollable bleeding events are just the tip of the iceberg, and the number of litigations filed against Janssen Pharmaceuticals (a division of Johnson & Johnson) and Bayer AG grew so much that they were consolidated into a Multi-District Litigation (MDL) presided over by Judge Eldon Fallon, in the United States District Court for the Eastern District of Louisiana, in New Orleans. In this particular Xarelto lawsuit, case number 2:14-cv-00159-CR, the plaintiff is a Vermont woman who is accusing the pharmaceutical company responsible for her father’s death.

The man from Vermont suffered from Atrial fibrillation, a cardiovascular condition for which Xarelto is prescribed to reduce the risk for blood clots and prevent strokes. The plaintiff who filed the Xarelto litigation claim that after using the medication for a short while, the man suffered from an injury that caused him to bleed. One of the most dangerous Xarelto side effects is uncontrollable bleeding, as there’s no known antidote available to reverse it. Unlike Warfarin and other similar blood thinners, Vitamin K or fresh platelet infusion are, in fact, ineffective, and once a bleeding event occurs, there’s nothing much that doctors could do to stop it from harming or killing a patient. When the man was hospitalized, the medical staff had no ways to stop the parenchymal hemorrhage (internal bleeding), although they managed to keep him alive for six full days. Eventually, he passed away because of the continuous blood loss they couldn’t stop otherwise.

 

This is just another Xarelto lawsuit filed against the manufacturers, as up to 1,700 cases have already been consolidated in the MDL number 2592. It is expected that many more cases will be filed before the trial is held.